Authors and Disclosures
Juan M. Pericàs1, Nicholas A. Di Prospero2, Quentin M. Anstee3,4, Peter Mesenbrinck5, Mette S. Kjær6, Jesús Rivera-Esteban1, Franz Koenig7, Elena Sena1, Raluca Pais8, Ramiro Manzano1, Joan Genescà1, Frank Tacke9 and Vlad Ratziu8 on behalf ofthe EU-PEARL NASH Investigators
1Liver Unit, Internal Medicine Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute for Research (VHIR), Barcelona, Spain
2Janssen Research and Development, Raritan, New Jersey, USA
3Liver Unit, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
4Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
5Analytics Department, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
6Novo Nordisk A/S, Bagsværd, Denmark
7Section for Medical Statistics, Medical University of Vienna, Vienna, Austria
8Department of Hepatology, Pitié-Salpetriere Hospital, University Paris 6, Paris, France
9Department of Hepatology and Gastroenterology, Charité –Universitätsmedizin Berlin, Berlin, Germany
Correspondence
Juan M. Pericàs, Liver Unit, Internal Medicine Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute for Research (VHIR), 08036 Barcelona, Spain. Email: juanmanuel.pericas@vallhebron.cat
Author Contributions
Juan Manuel Pericàs: Conceptualization (lead); funding acquisition (lead); investigation (lead); project administration (lead); supervision (lead); visualization (equal); writing – original draft (lead); writing – review and editing (lead). Nicholas A Di Prospero: Conceptualization (equal); investigation (equal); project administration (equal); visualization (lead); writing – original draft (lead). Quentin M Anstee: Investigation (equal); validation (equal); visualization (equal); writing – review and editing (equal). Peter Mesenbrink: Investigation (equal); methodology (equal); validation (equal); visualization (equal); writing – review and editing (equal). Mette Skalshøj Kjær: Investigation (lead); supervision (equal); validation (equal); visualization (equal); writing – review and editing (equal). Jesús Rivera-Esteban: Investigation (equal); visualization (equal); writing – original draft (supporting); writing – review and editing (equal). Franz Koenig: Investigation (equal); methodology (lead); validation (equal); visualization (equal); writing – review and editing (equal). Elena de Sena: Project administration (lead); validation (equal); visualization (equal); writing – original draft (supporting); writing – review and editing (supporting). Raluca Pais: Visualization (equal); writing – review and editing (equal). Ramiro Manzano-Nuñez: Investigation (equal); visualization (equal); writing – review and editing (equal). Joan Genescà: Funding acquisition (equal); investigation (equal); validation (equal); visualization (equal); writing – review and editing (equal). F. Tacke: Conceptualization (equal); validation (equal); visualization (equal); writing – review and editing (equal). Vlad Ratziu: Conceptualization (lead); investigation (lead); validation (equal); visualization (equal); writing – review and editing (equal).
Declaration of personal interests
JMP reports having received consulting fees from Boehringer-Ingelheim, MSD and Novo Nordisk. He has received speaking fees from Gilead, Intercept, and Novo Nordisk, and travel expenses from Gilead, Rubió, Pfizer, Astellas, MSD, CUBICIN, and Novo Nordisk. He has received educational and research support from Madrigal, Gilead, Pfizer, Astellas, Accelerate, Novartis, Abbvie, ViiV, and MSD. Funds from European Commission/EFPIA IMI2 853966–2, IMI2 777377, H2020 847989, and ISCIII PI19/01898. NAdP works for Janssen. QMA is Coordinator of the EU IMI-2 LITMUS consortium, which is funded by the EU Horizon 2020 programme and EFPIA. This multistakeholder consortium includes industry partners. He reports research Grant Funding: Allergan/Tobira, AstraZeneca, Boehringer-Ingelheim, Glaxo SmithKline, Glympse Bio, Intercept, Novartis Pharma AG, Pfizer Ltd. Consultancy: 89Bio, Abbvie/Allergan, Akero, Altimentiv, Altimmune, AstraZeneca, Axcella, Blade, BMS, BNN Cardio, Boehringer-Ingelheim, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Company Ltd., Galmed, Genentech, Genfit SA, Gilead, Grunthal, HistoIndex, Indalo, Intercept Pharma Europe Ltd., Inventiva, IQVIA, Janssen, Johnson & Johnson, Madrigal, MedImmune, Medpace, Merck, Metacrine, NGMBio, North Sea Therapeutics, Novartis, Novo Nordisk A/S, PathAI, Pfizer Ltd., Poxel, ProSciento, Raptor Pharma, Roche, Servier, Shionogi, Terns, The Medicines Company, Viking Therapeutics. Speaker: Abbott Laboratories, Allergan/Tobira, BMS, Clinical Care Options, Falk, Fishawack, Genfit SA, Gilead, Integritas Communications, Kenes, Medscape. Royalties: Elsevier Ltd. PM works for Novartis. MSK is an employee of and a shareholder in Novo Nordisk A/S. JG has received consulting fees from Boehringer-Ingelheim, speaking fees from Echosens and travel expenses from Gilead and Abbie. Funds from ISCIII PI18/00947 and PI21/00691. JRE has received speaking fees from Gilead. FT lab' work has been supported by the German Research Foundation (DFG, CRC/TR 362) and research grants from Gilead, Allergan, Bristol-Myers Squibb and Inventiva. VR consults for and Intercept, Novo Nordisk, Galmed, Poxel, NGM, Madrigal, Enyo, Sagimet, 89 Bio, Prosciento, Terns, and Theratechnologies, and received grants from Intercept and Gilead.
Declaration of funding interests
EU-PEARL has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853966–2. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and EFPIA and CHILDREN's Tumor Foundation, Global Alliance For TB Drug Development Non Profit Organisation, Springworks Therapeutics Inc. NASH EU-PEARL investigators: Nicholas A. DiProspero, Vlad Ratziu, Juan M. Pericàs, Mette S. Kjær, Quentin M. Anstee, Frank Tacke, Peter Mesenbrinck, Jesús Rivera-Esteban, Franz Koenig, Elena Sena, Ramiro Manzano, Joan Genescà, Raluca Pais, Leila Kara, Elias Meyer, Anna Duca, Timothy Kline, Anders Aaes-Jørgensen, Tania Balthaus, Natalie de Preville, Lingjiao Zhang, George Capuano, Salvatore Morello, Tobias Mielke, Sabina H. Penna, Martin Posch. This publication reflects only the author's views. The JU is not responsible for any use that may be made of the information it contains.